All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
Bookmark this article
During the 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem Meetings), the MDS Hub was pleased to speak with Charles Craddock, Queen Elizabeth Hospital Birmingham, Birmingham, UK. We asked, What does the FIGARO trial reveal about predictors of outcome post-transplant?
What does the FIGARO trial reveal about predictors of outcome post-transplant?
Craddock begins by outlining the trial aims and design, which investigated the use of the FLAMSA-Bu conditioning regimen in adult patients with AML. Craddock outlines the study results, noting that the presence of pretransplant measurable residual disease (MRD) is still associated with increased risk of relapse, and the most important predictor of outcome. Finally, Craddock discusses full donor T-cell chimerism, and reduced intensity conditioning (RIC) allograft strategies and mechanisms.
American Society for Transplantation and Cellular Therapy recommendations for allo-HSCT in MDS
Here we summarize the recent recommendations by the ASTCT relating to frequently asked questions on transplantation indications and factors impacting HSCT...
What are the new approaches for anemia treatment in MDS?
During the European School of Haematology (ESH) 2nd Translational Research Conference: Erythropoiesis Control and Ineffective Erythropoiesis - From Bench to Bedside, the MDS Hub spoke to Uwe...
Subscribe to get the best content related to MDS delivered to your inbox